Antibody Recruiting Small Molecules: A New Option for Prostate Tumor Therapy by PSMA Targeting

Biomarker-Based Metabolic Labeling for Redirected and Enhanced Immune Response

“…The targets will then be destructed by antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and/or antibody-dependent cellular cytotoxicity (ADCC) . Antibody-recruiting molecules (ARMs) are the most commonly used strategy to selectively label the surface of the target cells and have shown great therapeutic potentials. ,, They are synthetic bifunctional molecules containing a target-binding terminus (TBT), which recognize surface receptors of the target cell and antibody-binding terminus (ABT), which can recruit antibodies and activate immune responses. Using ARMs, the therapeutic effects of redirecting or enhancing immune responses toward otherwise immune-inert targets have been demonstrated in disease models such as cancer, ,− bacterial infection, , and virus infection. − However, immune therapy utilizing ARMs faces several challenges.…”